Prescribing information


Prescribing information

Welcome to the Dermatology patient management webinars page. Below you can access the latest educational webinars organised by Novartis and hosted by experts in the field of dermatology. The webinars are centred around two treatments with dermatology indications, Cosentyx® (secukinumab, moderate-severe plaque psoriasis) and Xolair® (omalizumab, chronic spontaneous urticaria).


Managing your plaque psoriasis and chronic spontaneous urticaria patients within the COVID-19 era and beyond.

Have you thought about how you'll manage patients after the pandemic, and what support is available? In this webinar, Dr Laura Savage, Dr Amy Foulkes and Dr John Reed discuss the shape of the patient consultation process and the additional support available to healthcare professionals and patients.




Cosentyx (secukinumab) is indicated for the treatment of moderate to severe plaque psoriasis in adults who are candidates for systemic therapy.1 Cosentyx is intended for use under the guidance and supervision of a physician experienced in the diagnosis and treatment of conditions for which Cosentyx is indicated.

Xolair (omalizumab) is indicated as add-on therapy for the treatment of chronic spontaneous urticaria in adult and adolescent (12 years and above) patients with inadequate response to H1-antihistamine treatment.2 Xolair treatment should be initiated by physicians experienced in the diagnosis and treatment of CSU.


  1. Cosentyx® Summary of Product Characteristics.
  2. Xolair® (omalizumab) 150 mg Summary of Product Characteristics.
Rate this content: 
No votes yet
UK | March 2021 | 109710

Ask Speakers


Medical Information Request

Adverse events should be reported. Reporting forms and information can be found at Adverse events should also be reported to Novartis via [email protected] or online through the pharmacovigilance intake (PVI) tool at
If you have a question about the product, please contact Medical Information on 01276 698370 or by email at [email protected]